Modafinil/armodafinil in the treatment of excessive daytime sleepiness

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

Introduction Excessive daytime sleepiness (EDS), a common problem that affects a substantial portion of the general population, is often the cardinal presenting feature of sleep disorders such as narcolepsy, shift work disorder (SWD), and obstructive sleep apnea (OSA). Modafinil, an effective wake-promoting agent with good safety and tolerability measures in addition to having low abuse potential, has been studied extensively in the treatment of daytime sleepiness associated with these sleep disorders, as well as other medical conditions such as Parkinson's disease, multiple sclerosis, depression, and chronic fatigue syndrome. More recently, a longer form of modafinil, armodafinil, the R-enantiomer, has been approved for the treatment of narcolepsy, SWD, and EDS associated with OSA. The following is a review of the therapeutic efficacy, tolerability and mode of action of modafinil and armodafinil for approved and off-label treatment of excessive sleepiness. Modafinil for the treatment of excessive sleepiness associated with OSA The treatment of choice for obstructive sleep apnea is continuous positive airway pressure (CPAP), which when used effectively, can alleviate respiratory disturbances, oxygen desaturations, and daytime sleepiness. However, a significant number of patients with treated obstructive sleep apnea continue to experience residual excessive sleepiness. Modafinil has been studied as a wake-promoting agent to alleviate symptoms of daytime sleepiness in patients with OSA treated by CPAP. A 4-week randomized, double-blind, placebo-controlled, parallel study evaluated the efficacy of modafinil (200 mg/d, week 1; 400 mg/d, weeks 2–4) in 157 patients with obstructive sleep apnea (Respiratory Disturbance Index (RDI) ≥ 15) and residual daytime sleepiness while compliant with CPAP therapy.

Original languageEnglish (US)
Title of host publicationSleepiness
Subtitle of host publicationCauses, Consequences and Treatment
PublisherCambridge University Press
Pages408-420
Number of pages13
ISBN (Electronic)9780511762697
ISBN (Print)9780521198868
DOIs
StatePublished - Jan 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Modafinil/armodafinil in the treatment of excessive daytime sleepiness'. Together they form a unique fingerprint.

  • Cite this

    Monderer, R., & Thorpy, M. J. (2011). Modafinil/armodafinil in the treatment of excessive daytime sleepiness. In Sleepiness: Causes, Consequences and Treatment (pp. 408-420). Cambridge University Press. https://doi.org/10.1017/CBO9780511762697.038